Stockscreener 앱 받기
10.92
10.27%
-1.25
시간 외 거래:
10.75
-0.17
-1.56%
전일 마감가:
$12.17
열려 있는:
$12.11
하루 거래량:
968.61K
Relative Volume:
1.61
시가총액:
$551.62M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-2.076
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+4.70%
1개월 성능:
+14.11%
6개월 성능:
+101.85%
1년 성능:
+17.55%
1일 변동 폭
$10.91
$12.14
1주일 범위
$10.24
$12.84
52주 변동 폭
$5.035
$12.84
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
10.92 | 614.76M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Chart based analysis of REGENXBIO Inc. trendsWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
REGENXBIO (NASDAQ:RGNX) Reaches New 12-Month HighTime to Buy? - MarketBeat
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - Eastern Progress
Why REGENXBIO Inc. is moving todayWeekly Profit Report & Long-Term Safe Return Strategies - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Is REGENXBIO Inc. trending in predictive chart modelsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
How to build a dashboard for REGENXBIO Inc. stockEarnings Summary Report & Free Real-Time Market Sentiment Alerts - newser.com
How cyclical is REGENXBIO Inc. (RB0) stock compared to rivalsJuly 2025 Market Mood & Safe Entry Trade Reports - newser.com
2-Year Results: REGENXBIO Presents ALTITUDE Phase II Data for Diabetic Retinopathy Oct 17 - Stock Titan
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29% - simplywall.st
Using data filters to optimize entry into REGENXBIO Inc.Insider Selling & Weekly Chart Analysis and Guides - newser.com
Is REGENXBIO Inc. stock positioned for digital transformationTrade Risk Report & Reliable Entry Point Alerts - newser.com
Is REGENXBIO Inc. (RB0) stock a top hedge fund pickTrade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
REGENXBIO (NASDAQ:RGNX) Trading 9.1% HigherShould You Buy? - MarketBeat
REGENXBIO's (RGNX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates REGENXBIO (RGNX) Buy Recommendation - Nasdaq
Regenxbio stock maintains Buy rating at H.C. Wainwright on gene therapy potential - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for RGNX with $34 Targ - GuruFocus
Viral Vector Gene Therapy Market Size Expects to Reach USD 38.39 Billion by 2034 - GlobeNewswire Inc.
Regenxbio Inc. Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet Amd - MarketScreener
REGENXBIO completes enrollment in wet AMD gene therapy trials - Investing.com
RGNX Completes Enrollment for Key Macular Degeneration Studies - GuruFocus
REGENXBIO completes enrollment in wet AMD gene therapy trials By Investing.com - Investing.com Nigeria
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for wet AMD - MarketScreener
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD - TradingView
1,200+ Enrolled: REGENXBIO Completes Largest Gene Therapy Wet AMD Program; Topline Q4 2026 - Stock Titan
What indicators show strength in REGENXBIO Inc.2025 Trading Recap & Low Risk High Win Rate Picks - newser.com
Combining price and volume data for REGENXBIO Inc.2025 Fundamental Recap & Expert Curated Trade Setup Alerts - newser.com
Will REGENXBIO Inc. stock gain from lower inflation2025 Performance Recap & Technical Pattern Based Signals - newser.com
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
Is REGENXBIO Inc a good long term investmentTechnology Stock Trends & Superior Capital Investment - earlytimes.in
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
REGENXBIO Inc. $RGNX Shares Sold by Voya Investment Management LLC - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Curran Simpson Sells 7,624 Shares of REGENXBIO (NASDAQ:RGNX) Stock - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares - Investing.com
REGENXBIO Inc Stock Analysis and ForecastMarket Liquidity Analysis & Affordable Investment Portfolio - earlytimes.in
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Promising DMD Gene Therapy: REGENXBIO's RGX-202 Shows Superior Results vs Natural History Controls - Stock Titan
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):